Sirtuins as Therapeutic Targets for Treating Cancer, Metabolic Diseases, and Neurodegenerative Diseases
Pharmaceuticals · 13.11.2025 · 18 (11) · 1723
DOI: 10.3390/ph18111723 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 13.11.2025. Verfasst von Maxwell Akantibila und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 242 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences, New Jersey Health Foundation.
Abstract (Originalsprache)
Sirtuins are NAD+-dependent enzymes that are conserved in all domains of life, including mammals, metazoans, plasmodia, yeast, bacteria, and archaea. In humans, there are seven isoforms (SIRT1 to 7), and they function in cellular homeostasis, aging, DNA repair, survival, metabolism, and stress responses. Recent advances highlight the diverse functions of sirtuins in the pathogenesis and progression of cancer, metabolic diseases, and neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD). To date, there is evidence that all seven isoforms contribute to cancer development, while SIRT1-3 and 6 contribute to metabolic and neurodegenerative diseases. Modulators of sirtuin activity are being actively explored to understand their biological and molecular mechanisms and potential for the treatment of various diseases. In this review, we begin with a broad discussion of post-translational modifications, protein deacetylation, and the mechanism of action of sirtuins. Next, we discuss the role of sirtuins in cancer, including inhibitors and activators of sirtuin activity as cancer therapies. In addition, we discuss the relationship of sirtuins to metabolic diseases and as possible treatment targets. Finally, we discuss the role of sirtuins in AD, PD, and HD, and sirtuin modulators for treating neurodegenerative diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA.
- Department of Chemistry and Biochemistry, Rowan University, Glassboro, NJ 08028, USA.
ORCID-Profile: Maxwell Akantibila, Valerie J Carabetta
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
- New Jersey Health Foundation
Zitieren
APA
Akantibila, M., & Carabetta, V. J. (2025). Sirtuins as Therapeutic Targets for Treating Cancer, Metabolic Diseases, and Neurodegenerative Diseases. Pharmaceuticals, 18(11), 1723. https://doi.org/10.3390/ph18111723
Vancouver
Akantibila M, Carabetta VJ. Sirtuins as Therapeutic Targets for Treating Cancer, Metabolic Diseases, and Neurodegenerative Diseases. Pharmaceuticals. 2025;18(11):1723. doi:10.3390/ph18111723
BibTeX
@article{Akantibila2025,
author = {Akantibila, Maxwell and Carabetta, Valerie J},
title = {Sirtuins as Therapeutic Targets for Treating Cancer, Metabolic Diseases, and Neurodegenerative Diseases},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {11},
pages = {1723},
doi = {10.3390/ph18111723}
}
EUVIMED